Phase II study of single agent gemcitabine in patients with hormone refractory prostate cancer (HRPC).

被引：0

作者：

Nilsson, S ^{[1
]}

Holmberg, M ^{[1
]}

Ljung, G ^{[1
]}

Pettersson-Skjold, D ^{[1
]}

Blom, R ^{[1
]}

Ullén, A ^{[1
]}

Westberg, R ^{[1
]}

Nilsson, I ^{[1
]}

Lennernas, B ^{[1
]}

机构：

[1] Swedish Prostate Canc Study Grp, Stockholm, Sweden

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4705

引用

页码：432S / 432S

页数：1

共 50 条

[41] Predictive modelling in hormone-refractory prostate cancer (HRPC) [J].

Joaquim Bellmunt ;

Joan Carles ;

Joan Albanell .

Clinical and Translational Oncology, 2009, 11 :82-85

[42] Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients (HRPC): A single institution experience [J].

Coronado, C. ;

Rodriguez-Antolin, A. ;

Sepulveda, J. ;

Diaz Padilla, I. ;

Holgado, E. ;

Garcia Escobar, I. ;

Castellano, D. E. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[43] A PHASE 2 STUDY OF PATUPILONE IN PATIENTS WITH METASTATIC HORMONE REFRACTORY PROSTATE CANCER (HRPC) WHO HAVE PROGRESSED AFTER DOCETAXEL [J].

Chi, K. N. ;

Beardsley, E. ;

Eigl, B. ;

Venner, P. ;

Hotte, S. J. ;

Winquist, E. ;

Ko, Y. J. ;

Saad, F. .

ANNALS OF ONCOLOGY, 2008, 19 :189-189

[44] The efficacy of gemcitabine in controlling pain and improving performance status in men with hormone-refractory prostate cancer (HRPC) [J].

Ahmann, FR ;

Burris, HA ;

Nguyen, B .

EUROPEAN JOURNAL OF CANCER, 1997, 33 :148-148

[45] A phase II study of paclitaxel and vinorelbine (Pac-Vin) in hormone-refractory metastatic prostate cancer (HRPC): A final update [J].

Sewak, S. ;

Kosmider, S. ;

Ganju, V. ;

Woollett, A. ;

Le, B. ;

Yeo, E. ;

Henry, M. ;

Bell, R. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)

[46] EFFICACY OF LOW-DOSE KETOCONAZOLE IN HORMONE REFRACTORY PROSTATE CANCER PATIENTS (HRPC). A SINGLE INSTITUTION EXPERIENCE [J].

Coronado, C. ;

Castellano, D. ;

Garcia Rodriguez, L. ;

Garcia Escobar, I. ;

Diaz-Padilla, I. ;

Sepulveda, J. ;

Rodriguez Antolin, A. ;

Cortes-Funes, H. .

ANNALS OF ONCOLOGY, 2008, 19 :200-201

[47] A phase II study of temozolomide in hormone-refractory prostate cancer [J].

van Brussel, JP ;

Busstra, MB ;

Lang, MS ;

Catsburg, T ;

Schröder, FH ;

Mickisch, GH .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 45 (06) :509-512

[48] A phase II study of temozolomide in hormone-refractory prostate cancer [J].

Jérôme P. van Brussel ;

Martijn B. Busstra ;

Margreet S. Lang ;

Tilly Catsburg ;

Fritz H. Schröder ;

Gerald H. Mickisch .

Cancer Chemotherapy and Pharmacology, 2000, 45 :509-512

[49] A randomized phase II study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer (HRPC) [J].

Chi, K. N. ;

Hotte, S. J. ;

Yu, E. ;

Eigl, B. J. ;

Tannock, I. ;

Saad, F. ;

North, S. ;

Powers, J. ;

Eisenhauer, E. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)

[50] Gefitinib (IressaTM) combined with endocrine manipulation in patients with hormone refractory prostate cancer (HRPC). [J].

de Braud, FG ;

Curigliano, G ;

De Pas, T ;

Noberasco, C ;

Renne, G ;

Zorzino, L ;

Scardino, E ;

Del Monaco, D ;

De Cobelli, O .

CLINICAL CANCER RESEARCH, 2005, 11 (24) :9022S-9022S

← 1 2 3 4 5 →